- Conditions
- Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
- Device · Combination Product
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 9,914
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Knee Injuries and Disorders, Shoulder Disease, Shoulder Injuries
- Interventions
- C Scope Visualization System
- Device
- Lead sponsor
- CIT Ortho
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Henderson, Nevada
- Conditions
- Diabetic Macular Edema
- Interventions
- Dexamethasone implant, Aflibercept
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Berzosertib, Biospecimen Collection, Carboplatin, Computed Tomography, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 34
- States / cities
- Los Angeles, California • Newport Beach, California • Aventura, Florida + 25 more
- Conditions
- Cleft Palates
- Interventions
- Unasyn, saline solution
- Drug · Other
- Lead sponsor
- Joseph Losee
- Other
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Phenylketonuria (PKU)
- Interventions
- Kuvan
- Drug
- Lead sponsor
- Dr. Linda Randolph
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse
- Interventions
- brentuximab vedotin, rituximab, vincristine, cyclophosphamide, prednisone, doxorubicin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Tarlatamab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Miami Beach, Florida • Stuart, Florida + 6 more
- Conditions
- Nicotine Dependence
- Interventions
- NicVAX, [123I]5-IA-85380, Nicotine bitartrate
- Biological · Radiation · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Hysteroscopy
- Interventions
- Green Draping Procedure, Full Draping Procedure
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Cesarean Section Complications, Pain, Opioid Use
- Interventions
- Liposomal bupivacaine, Bupivacaine Hydrochloride, saline
- Drug · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Childhood Absence Epilepsy, Juvenile Absence Epilepsy
- Interventions
- Brivaracetam Film-coated tablet, Brivaracetam oral solution
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • New Brunswick, New Jersey • Winston-Salem, North Carolina
- Conditions
- Cardiac Transplant Disorder
- Interventions
- Stratified Transplant Survival Metric, SRTR Information Format
- Other
- Lead sponsor
- Carnegie Mellon University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Advanced Follicular Lymphoma
- Interventions
- Obinutuzumab, Bendamustine, Cyclophosphamide, Doxorubicin, Prednisone/Prednisolone/Methylprednisolone, Vincristine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Boulder, Colorado • Bethesda, Maryland • Florham Park, New Jersey + 3 more
- Conditions
- Bullying of Child, Bullying
- Interventions
- STAC
- Behavioral
- Lead sponsor
- Klein Buendel, Inc.
- Industry
- Eligibility
- 11 Years to 80 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Golden, Colorado • Boise, Idaho
- Conditions
- Cervical Cancer
- Interventions
- Introducer "calla" device, Interviews only
- Device · Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 305 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cancer of the Breast
- Interventions
- Axillary Reverse Mapping
- Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Pancreatic Adenocarcinoma, Metastatic
- Interventions
- Nab-paclitaxel, Gemcitabine, VCN-01
- Drug · Genetic
- Lead sponsor
- Theriva Biologics SL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Newport Beach, California • Sacramento, California • Louisville, Kentucky + 4 more
- Conditions
- Herpes Simplex
- Interventions
- Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Rochester, New York
- Conditions
- Influenza
- Interventions
- Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,659 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 10
- States / cities
- Chandler, Arizona • Miami, Florida • Newton, Kansas + 7 more
- Conditions
- Colorectal Cancer
- Interventions
- Simethicone, Placebo, sodium sulfate/potassium sulfate/magnesium sulfate solution
- Drug
- Lead sponsor
- MercyOne Des Moines Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Clive, Iowa
- Conditions
- Atherosclerosis, Intermittent Claudication, Peripheral Vascular Diseases
- Interventions
- Ferritin reduction to 25 ng/ml by phlebotomy
- Procedure
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 21 Years and older
- Enrollment
- 1,277 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2005
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • No. Little Rock, Arkansas • Long Beach, California + 20 more
- Conditions
- Alcoholic Hepatitis
- Interventions
- DUR-928 (Moderate AH), DUR-928 (Severe AH)
- Drug
- Lead sponsor
- Craig James McClain
- Other
- Eligibility
- 21 Years to 67 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Dysphagia of Newborn
- Interventions
- Pacifier-Activated Lullaby (PAL) Therapy
- Device
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 34 Weeks to 36 Weeks
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Orlando, Florida